Values First Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Values First Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-471	Closed	-$58.8K	–	289
2024 Q3	$58.8K	Buy	+471	New	+$65.1K	0.03%	219
2023 Q2	–	Sell	-1	Closed	-$87	–	316
2023 Q1	$87	Buy	+1	New	+$130	﹤0.01%	349
2021 Q2	–	Sell	-4,589	Closed	-$342K	–	155
2021 Q1	$342K	Sell	4,589 -1,741	-28%	-$161K	0.25%	119
2020 Q4	$1.08M	Buy	6,330 +1,317	+26%	+$195K	0.86%	45
2020 Q3	$704K	Sell	5,013 -1,414	-22%	-$215K	0.65%	54
2020 Q2	$1.03M	Sell	6,427 -1,335	-17%	-$182K	1.02%	41
2020 Q1	$759K	Sell	7,762 -999	-11%	-$114K	0.91%	41
2019 Q4	$1.13M	Buy	+8,761	New	+$884K	1.09%	37

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Values First Advisors's SRPT Position: Q4 2024 in Review

Values First Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 471 shares — an estimated $58.8K sold.

Values First Advisors first reported a position in SRPT in Q4 2019 and held it in 8 quarters. The position peaked at $1.13M in Q4 2019. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Values First Advisors reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Values First Advisors sold 471 Sarepta Therapeutics shares in Q4 2024, an estimated $58.8K.
Values First Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 8 quarters.
Values First Advisors's Sarepta Therapeutics position peaked at $1.13M in Q4 2019.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.